|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.570 USD | -6.55% |
|
+8.28% | -0.63% |
| 06-29 | Outlook Therapeutics Regains Nasdaq Compliance | MT |
| 06-16 | Outlook Therapeutics Shares Surge After FDA Accepts Resubmitted Wet AMD Application | DJ |
Company Valuation: Outlook Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: September | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 380.5 | 275.9 | 57.51 | 126.3 | 47.08 | 189.8 | - | - |
| Change | - | -27.49% | -79.15% | 119.63% | -62.73% | 303.01% | - | - |
| Enterprise Value (EV) | 380.5 | 275.9 | 57.51 | 126.3 | 47.08 | 189.8 | 189.8 | 189.8 |
| Change | - | -27.49% | -79.15% | 119.63% | -62.73% | 303.01% | 0% | 0% |
| P/E | -6.2x | -3.94x | -0.92x | -1.32x | -0.59x | -3.2x | -5.23x | -10.5x |
| PBR | 71.9x | 29.6x | - | - | - | - | - | - |
| PEG | - | 0.3x | 0x | 0.1x | 0x | 0x | 0.1x | 0.2x |
| Capitalization / Revenue | - | - | - | - | 33.3x | 158x | 4.15x | 8.31x |
| EV / Revenue | - | - | - | - | 0x | 158x | 4.15x | 8.31x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -3.81x | -5.73x | -12.4x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -7 | -6.2 | -4.8 | -4.06 | -1.79 | -0.49 | -0.3 | -0.15 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | 1.413 | 1.2 | 45.73 | 22.84 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -51.73 | -63.07 | -53.13 | -71.7 | -67.06 | -49.75 | -33.11 | -15.3 |
| Net income 1 | -53.16 | -66.05 | -58.98 | -75.37 | -62.42 | -52.18 | -42.33 | -14.53 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 43.400 | 24.400 | 4.420 | 5.340 | 1.060 | 1.570 | 1.570 | 1.570 |
| Nbr of stocks (in thousands) | 8,767 | 11,307 | 13,012 | 23,656 | 44,420 | 120,863 | - | - |
| Announcement Date | 12/22/21 | 12/29/22 | 12/22/23 | 12/27/24 | 12/19/25 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.2x | - | - | - | 190M | |
| 35.38x | 6.18x | 19.12x | 0.93% | 50.73B | |
| -23.4x | 342.07x | -22.1x | -.--% | 39.73B | |
| 25.29x | 2.8x | 12.09x | -.--% | 34.69B | |
| 45.73x | 4.51x | 28.9x | -.--% | 33.21B | |
| 27.05x | 7.93x | 19.91x | 0.42% | 26.76B | |
| 31.75x | 5.12x | 23.32x | -.--% | 15.37B | |
| 23.95x | 2.04x | 8.96x | 1.12% | 13.78B | |
| 23.74x | 1.89x | 11.45x | -.--% | 12.85B | |
| Average | 20.70x | 46.57x | 12.71x | 0.31% | 25.26B | |
| Weighted average by Cap. | 22.47x | 63.82x | 11.59x | 0.32% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- OTLK Stock
- Valuation Outlook Therapeutics, Inc.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
